| P/E (FY) | — | Sales (TTM) | $61.6M |
| Earnings (TTM) | -$31.8M | ROE | — |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | — | Trading Days | 5277 |
| 52W High | 103.20 |
| 52W Low | 7.94 |
| % Off High | −87.94% |
| YTD | −47.47% | 1Y | −38.06% |
| 3Y | −91.53% | 5Y | −96.01% |
| 10Y | −99.36% | Since incept. (ann.) | −18.49% |
| Ann. Volatility (1Y) | 150.75% | Ann. Volatility (3Y) | 127.14% |
| Sharpe (1Y) | 0.32 | Sharpe (3Y) | −0.09 |
| Max Drawdown (1Y) | −85.26% | Max Drawdown (3Y) | −94.26% |
| Beta (3Y, vs SPY) | 0.88 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| IDXX | IDEXX LABORATORIES INC /DE | $44.93B | 43.5 |
| LNTH | Lantheus Holdings, Inc. | $6.68B | 30.1 |
| CLDX | Celldex Therapeutics, Inc. | $2.79B | — |
| NEOG | NEOGEN CORP | $2.00B | — |
| NTLA | Intellia Therapeutics, Inc. | $1.52B | — |
| QDEL | QuidelOrtho Corp | $1.14B | — |
| ACHV | ACHIEVE LIFE SCIENCES, INC. | $634.4M | — |
| MYGN | MYRIAD GENETICS INC | $502.5M | — |
| TKNO | Alpha Teknova, Inc. | $260.0M | — |
| IMDX | Insight Molecular Diagnostics Inc. | $148.9M | — |
| ICCC | IMMUCELL CORP /DE/ | $101.7M |
| QCLS | Q/C TECHNOLOGIES, INC. | $25.3M | — |
